NBE Therapeutics' unique selling proposition (USP) in the field of Antibody Drug Conjugate (ADC) Development lies in the combination of know-how and technologies available in a single Biotech start-up entity. The majority of players in the ADC field mostly cover one or two aspects of ADC development, e.g. a conjugation approach or a novel toxin, which requires partnering and licenses to access the missing aspects of an ADC. Since incorporation, NBE-Therapeutics has pursued its vision to develop enabling and proprietary technologies allowing NBE-Therapeutics and its partners to address all aspects of ADC discovery and development.
Except for target research and validation, which is covered by academic partnerships, NBE-Therapeutics is uniquely positioned to develop novel, first- and best-in-class ADCs against any desired cancer cell target.
As a result of these capabilities, the intellectual property portfolio of the company covers technology platforms as well as novel composition of matter of therapeutic antibodies and ADCs.
- Barcelona, 2017-05-18 - NBE-Therapeutics invited to present at the 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
- London, 2017-05-15 - NBE-Therapeutics will present at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.
- Boston, MA, USA, 2017-05-02 - NBE-Therapeutics to present update on R&D activities at 2017-PEGS conference